Allakos logo

AllakosNASDAQ: ALLK

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

19 July 2018

Next earnings report:

14 March 2025

Last dividends:

N/A

Next dividends:

N/A
$103.64 M
-97%vs. 3y high
46%vs. sector
-vs. 3y high
-vs. sector
-83%vs. 3y high
50%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Sat, 16 Nov 2024 00:13:55 GMT
$1.16$0.00(0.00%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

ALLK Latest News

All You Need to Know About Allakos (ALLK) Rating Upgrade to Buy
zacks.com11 November 2024 Sentiment: POSITIVE

Allakos (ALLK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Allakos Runs Up Into A Near-Term Catalyst
seekingalpha.com07 November 2024 Sentiment: POSITIVE

Allakos shifted focus to AK006 in 2024 after lirentelimab's failure in phase 2 trials for atopic dermatitis and chronic spontaneous urticaria. Phase 1 work with intravenous and subcutaneous AK006 demonstrates that the drug may not require frequent dosing, which may be important given potential competition from oral remibrutinib. Upcoming Q1'25 data from a randomized, double-blind, placebo-controlled trial of IV AK006 in over 30 CSU patients is a near-term catalyst.

Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results
globenewswire.com07 August 2024 Sentiment: POSITIVE

SAN CARLOS, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the second quarter ended June 30, 2024.

Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile
globenewswire.com25 June 2024 Sentiment: POSITIVE

– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments –– Skin biopsies from subjects treated with AK006 show high receptor occupancy –– AK006 was well-tolerated with a favorable safety profile –

The Schall Law Firm Begins Probe Into Claims Against Allakos Inc And Urges Affected Investors To Participate
accesswire.com25 June 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / June 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Allakos" or "the Company") (NASDAQ:ALLK) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Begins Probe Into Claims Against Allakos Inc And Urges Affected Investors To Participate
accesswire.com21 June 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / June 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Allakos" or "the Company") (NASDAQ:ALLK) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Initiates Investigation Into Allegations Against Allakos Inc And Encourages Impacted Investors To Get Involved
accesswire.com20 June 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / June 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Allakos" or "the Company") (NASDAQ:ALLK) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Claims Against Allakos Inc The Schall Law Firm Begins Probe And Urges Affected Investors To Participate
accesswire.com19 June 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / June 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Allakos" or "the Company") (NASDAQ:ALLK) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Claims Against Allakos Inc Schall Law Firm Begins Probe And Urges Affected Investors To Participate
accesswire.com17 June 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / June 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Allakos" or "the Company") (NASDAQ:ALLK) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Allegations Against Allakos Inc.: Schall Law Firm Initiates Investigation And Encourages Impacted Investors To Get Involved
accesswire.com11 June 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / June 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Allakos" or "the Company") (NASDAQ:ALLK) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

  • 1(current)
  • 2

What type of business is Allakos?

Allakos Inc. operates as a clinical-stage biopharmaceutical company. The company is developing antolimab (AK002) for the treatment of eosinophilic gastritis and eosinophilic esophagitis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in Redwood City, California.

What sector is Allakos in?

Allakos is in the Healthcare sector

What industry is Allakos in?

Allakos is in the Biotechnology industry

What country is Allakos from?

Allakos is headquartered in United States

When did Allakos go public?

Allakos initial public offering (IPO) was on 19 July 2018

What is Allakos website?

https://www.allakos.com

Is Allakos in the S&P 500?

No, Allakos is not included in the S&P 500 index

Is Allakos in the NASDAQ 100?

No, Allakos is not included in the NASDAQ 100 index

Is Allakos in the Dow Jones?

No, Allakos is not included in the Dow Jones index

When was Allakos the previous earnings report?

No data

When does Allakos earnings report?

The next expected earnings date for Allakos is 14 March 2025